Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02769442 · ClinicalTrials.gov registry record · NA

Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED

A NA study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
600
Enrollment target

NCT02769442 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 600 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02769442, a NA study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
600 participants
Enrollment target

Study Summary

A randomized prospective comparison of two FDA approved intravenous catheters in the emergency department setting. The Terumo SurFlash Plus offers novel technologies that promise to increase intravenous access success rates and decrease blood contamination of the insertion site. This study would analyze these properties in our busy, urban emergency department setting where time and safety of intravenous access are most critical.

Interventions

  • DEVICE Terumo SurFlash Plus catheter
  • DEVICE BD Insyte Autoguard catheter

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2016-06
Est. Completion 2016-10
Phase NA

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT02769442

The ClinicalTrials.gov registry entry for NCT02769442 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Terumo SurFlash Plus catheter is the first listed.

NCT02769442 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02769442 about?

NCT02769442 is a clinical study titled "Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED". A randomized prospective comparison of two FDA approved intravenous catheters in the emergency department setting. The Terumo SurFlash Plus offers novel technologies that promise to increase intravenous access success rates and decrease blood contamination of the insertion site. This study would ana...

What is the current status of trial NCT02769442?

This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2016-06. Estimated completion is 2016-10.

What interventions are being tested in trial NCT02769442?

The interventions under investigation include: Terumo SurFlash Plus catheter (DEVICE), BD Insyte Autoguard catheter (DEVICE).

Who is sponsoring clinical trial NCT02769442?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.